NCT01587352View on ClinicalTrials.gov

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 29, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Uveal MelanomaStage IV Uveal Melanoma AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (3)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

37232

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

Institut Curie Paris

UNKNOWN

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Moffitt Cancer Center P2C

UNKNOWN

lead

National Cancer Institute (NCI)

NIH

NCT01587352 - Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | Biotech Hunter | Biotech Hunter